EN
TR
Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS
Abstract
Aim: In this study, it was aimed to investigate the effects of beta glucan (BG) on the experimental colitis model created by using trinitrobenzene sulfonic acid (TNBS).
Material and Methods: Thirty-two Wistar Albino rats were divided equally into four groups as sham control, TNBS, TNBS-BG3, and TNBS-BG10 groups. While saline was administrated to sham group, TNBS was administered intrarectally to the TNBS groups under anesthesia. BG was administered at a dose of 100 mg/kg by oral gavage, intragastrically, for 3 days (TNBS+3) to the TNBS-BG3 group and for 10 days (7+TNBS+3) to the TNBS-BG10 group. At the end of the study, macroscopic, histological and biochemical tests were applied to the colon tissues taken.
Results: It was determined by histopathological scoring and biochemical results that BG administration caused positive effects on colon damage due to colitis. Malondialdehyde level and myeloperoxidase activity were found to be significantly higher in the TNBS group compared to the other groups (p=0.003 and p<0.001, respectively). Antioxidant levels increased in BG treated groups compared to TNBS group. While this increase was statistically significant among glutathione levels (p<0.001), it was not statistically significant in catalase enzyme activity (p=0.218). BG administration reduced the increase in lipid peroxidation and leukocyte infiltration level in the colon tissue. Positive changes due to the prophylactic effect of BG were determined in histological and biochemical results.
Conclusion: BG administration has been found to show anti-inflammatory and antioxidant properties, and BG has a treatment potential in reducing colon tissue damage due to TNBS-induced colitis.
Keywords
Supporting Institution
Aydin Adnan Menderes University, Scientific Research Projects Committee
Project Number
TPF-13021
References
- Petronis A, Petroniene R. Epigenetics of inflammatory bowel disease. Gut. 2000;47(2):302-6.
- Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6(1):8-15.
- Norris AA, Lewis AJ, Zeitlin IJ. Changes in colonic tissue levels of inflammatory mediators in a guinea-pig model of immune colitis. Agents Actions. 1982;12(1-2):243-6.
- Selve N. Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases. Agents Actions. 1992;Spec No:C15-7.
- Podolsky D. Inflamatory bowel disease. N Engl J Med. 2002;347(6):417-29.
- Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380(9853):1606-19.
- Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.
- Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988;33(3 Suppl):6S-15S.
Details
Primary Language
English
Subjects
Clinical Sciences
Journal Section
Research Article
Publication Date
December 30, 2021
Submission Date
September 5, 2021
Acceptance Date
November 18, 2021
Published in Issue
Year 2021 Volume: 23 Number: 3
APA
Tokmak, D., Şirinyıldız, F., & Ek, R. O. (2021). Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Medical Journal, 23(3), 276-281. https://doi.org/10.18678/dtfd.991389
AMA
1.Tokmak D, Şirinyıldız F, Ek RO. Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Med J. 2021;23(3):276-281. doi:10.18678/dtfd.991389
Chicago
Tokmak, Deren, Ferhat Şirinyıldız, and Rauf Onur Ek. 2021. “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”. Duzce Medical Journal 23 (3): 276-81. https://doi.org/10.18678/dtfd.991389.
EndNote
Tokmak D, Şirinyıldız F, Ek RO (December 1, 2021) Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Medical Journal 23 3 276–281.
IEEE
[1]D. Tokmak, F. Şirinyıldız, and R. O. Ek, “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”, Duzce Med J, vol. 23, no. 3, pp. 276–281, Dec. 2021, doi: 10.18678/dtfd.991389.
ISNAD
Tokmak, Deren - Şirinyıldız, Ferhat - Ek, Rauf Onur. “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”. Duzce Medical Journal 23/3 (December 1, 2021): 276-281. https://doi.org/10.18678/dtfd.991389.
JAMA
1.Tokmak D, Şirinyıldız F, Ek RO. Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Med J. 2021;23:276–281.
MLA
Tokmak, Deren, et al. “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”. Duzce Medical Journal, vol. 23, no. 3, Dec. 2021, pp. 276-81, doi:10.18678/dtfd.991389.
Vancouver
1.Deren Tokmak, Ferhat Şirinyıldız, Rauf Onur Ek. Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Med J. 2021 Dec. 1;23(3):276-81. doi:10.18678/dtfd.991389
